Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study

Utsav Joshi, Adheesh Bhattarai, Suman Gaire, Simrat Gill, Vishakha Agrawal, Sumeet Kumar Yadav, Soon Khai Low, Prajwal Dhakal, Vijaya Raj Bhatt, Peter A. Kouides

Research output: Contribution to journalArticlepeer-review

Abstract

Prior studies report a greater incidence of second primary malignancy (SPM) among patients with myeloproliferative neoplasms, although the true risk in primary myelofibrosis (PMF) has not been elucidated. We utilized the Surveillance, Epidemiology, and End Results database to evaluate the risk of SPM in PMF patients and analyzed the effects of sociodemographic factors on the risk of SPM. Out of 5273 patients, 385 patients (7.30%) developed SPM. SPM occurred at SIR of 1.95 (95% CI 1.76–2.15) and AER of 149.01 per 10,000 population. A significantly higher incidence of melanoma (SIR 1.76, 95% CI 1.01–2.86), lymphoma (SIR 3.38, 95% CI 2.28–4.83), and leukemia (SIR 27.19, 95% CI 23.09-31.81) was observed. The risk was significantly higher in patients ≤60 years, males, chemotherapy recipients, within 5 years of PMF diagnosis, and for PMF diagnosed after 2009.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2022

Keywords

  • incidence
  • leukemia
  • melanoma
  • Primary myelofibrosis
  • second primary malignancy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study'. Together they form a unique fingerprint.

Cite this